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The Beneficial Effects of Apical Sodium-Dependent Bile Acid
Transporter Inactivation Depend on Dietary Fat Composition
Ivo P. van de Peppel,* Anuradha Rao, Marleen B. Dommerholt, Laura Bongiovanni,
Rachel Thomas, Alain de Bruin, Saul J. Karpen, Paul A. Dawson, Henkjan J. Verkade,
and Johan W. Jonker*
Scope: The apical sodium-dependent bile acid transporter
(ASBT, SLC10A2) is important in the enterohepatic cycling of bile acids
and thereby in the intestinal absorption of lipids. ASBT inhibition has been
shown to improve aspects of the metabolic syndrome, but the underlying
mechanisms have remained unclear. Here, the effect of ASBT inhibition
on the uptake of specific fatty acids and its consequences for diet-induced
obesity and non-alcoholic fatty liver disease (NAFLD) are investigated.
Methods: Intestinal fat absorption is determined in mice receiving an ASBT
inhibitor and in Asbt−/− mice. Metabolic disease development is determined
in Asbt−/− mice receiving a low-fat control diet (LFD) or high-fat diet (HFD)
rich in saturated fatty acids (SFAs) or PUFAs.
Results: Both ASBT inhibition and Asbt gene inactivation reduce total fat
absorption, particularly of SFAs. Asbt gene inactivation lowers bodyweight
gain, improves insulin sensitivity, and decreases the NAFLD activity score
upon feeding a HFD rich in SFAs, but not in PUFAs.
Conclusions: The beneficial metabolic effects of ASBT inactivation on diet-
induced obesity depend on decreased intestinal absorption of SFAs, and thus
on the dietary fatty acid composition. These findings highlight the importance
of dietary fatty acid composition in the therapeutic effects of ASBT inhibition.
1. Introduction
Obesity is an important risk factor for the development
of type 2 diabetes mellitus (T2DM) and non-alcoholic fatty
liver disease (NAFLD) also known as metabolic (dysfunction)
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associated fatty liver disease
(MAFLD).[1,2] Recently, bile acids (BAs)
and their receptors have emerged as
important regulators of glucose and
lipid metabolism and as potential targets
for the treatment of obesity and related
metabolic disorders.[3,4] BAs play an
important role in the absorption and
digestion of dietary lipids. This process
starts in the stomach and intestinal
lumen where triglycerides (TGs) are
hydrolyzed by gastric and pancreatic
lipases into glycerol, monoacylglyc-
erols, and free fatty acids (FFAs). FFAs,
cholesterol and fat-soluble vitamins are
solubilized as mixed micelles by BAs, a
process that facilitates the transport of
these hydrophobic compounds across
the aqueous phase of the small intestinal
lumen and the unstirred water layer over-
lying the intestinal epithelium, for subse-
quent translocation into the enterocyte.[5]
BAs must be present above their critical
micelle concentration (CMC) to promote
efficient lipid absorption. Reported
values for the CMCs vary for different BA species and depend on
the analytic methods and conditions used.[6]
Under physiological conditions, BA homeostasis is tightly reg-
ulated by the BA-activated nuclear receptor, farnesoid x receptor
(FXR), in the liver and intestine. The enterohepatic circulation
of BAs is highly efficient and results in intestinal reabsorption
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of ≈95% of BAs per cycle. Under intestinal bile-deficient con-
ditions, lipolysis of TGs continues but fat absorption is slower
and less efficient, and consequently extended into more distal
segments of the intestine.[7] The most important BA-activated
receptors involved in their metabolic effects are FXR and the
G-protein coupled BA receptor 1 (GPBAR1, synonyms GPCR19
or TGR5).[8] These receptors can be modulated directly via
receptor (ant)agonism or indirectly via altering the enterohepatic
circulation of BAs.
Interruption of the enterohepatic circulation of BAs by inhi-
bition or genetic inactivation of the apical sodium-dependent
BA transporter (ASBT, SLC10A2) in mice decreased intestinal
lipid absorption.[9–11] Micellar solubilization is most important
for hydrophobic lipids such as cholesterol, fat-soluble vitamins,
and (long-chain) saturated fatty acids (SFAs). Studies using
cholestatic and bile-deficient rat models showed more pro-
nounced effects on absorption of long chain SFAs than on long
chain PUFAs.[12,13] ASBT deficiency, however, not only decreases
total BA concentrations, but also shifts the BA composition
towards a more hydrophobic profile containing more cholic
acid (CA) and less muri-cholic acid (MCA).[9,11,14] Hydrophobic
BAs have a lower CMC and are more efficient in micellar
solubilization.[15,16] Therefore, it was hypothesized that the
increase in biliary hydrophobicity relatively preserves lipid ab-
sorption in Asbt−/− mice.[9] However, we recently demonstrated
that fractional cholesterol absorption is nearly abrogated (<5%)
in Asbt−/− mice despite having more hydrophobic bile compared
to control mice.[11]
In various in vivo models, ASBT inhibition improves obesity-
related disorders such as NAFLD and hyperglycemia.[10,14,17–20]
The mechanism underlying these changes has remained
unclear.[21] Conversely, two studies using an ASBT inhibitor
treatment for non-alcoholic steatohepatitis (NASH) did not
show improvements in hepatic outcomes.[10,22] The intestinal
specific ASBT inhibitor (ASBTi) SC-435 reduced hepatic fat
accumulation and improved glucose tolerance in mice on a
Western type diet.[14] Recently, we showed that the beneficial
effects of SC-435 on NAFLD/NASH were attenuated when
feeding a choline-deficient amino acid defined (CDAA) diet.[10]
Interestingly, the CDAA diet also abolished the effects of SC-435
on fat absorption suggesting a potential relationship between
the two effects. In the current study, we examined the effect of
ASBT inhibition on the absorption of different fatty acids from
the diet and the effect of genetic ASBT inactivation on high
fat diet (HFD) induced obesity and NAFLD. Modulation of the
dietary fatty acid composition in combination with genetic ASBT
inactivation allowed us to assess the effects of specific fatty acid
absorption on the development of metabolic disease.
2. Results
2.1. ASBT Inhibition Differentially Affects the Absorption of Fatty
Acid Species
To determine the role of ASBT in the absorption of different
fatty acids, we first examined the effect of the ASBTi. There
were no differences in food intake, bodyweight, liver weight, or
hepatic TG levels between the two groups (Table S2, Supporting
Information). Total hepatic cholesterol content, however, was
decreased by the ASBTi (Table S2, Supporting Information).
Overall, intestinal fat absorption was reduced by about 8%
with ASBTi treatment (Figure 1A, 92.4 vs 84.7%, p < 0.001).
Absorption of MUFAs was reduced in ASBTi treated mice, by
1.8% for vaccenic acid (C18:1𝜔7) and by 4.0% for oleic acid
(C18:1𝜔9) (Figure 1B). Absorption of the trans-fatty acid (TFA),
elaidic acid (C18:1t9), was reduced by 5.9% in the ASBTi-treated
mice (Figure 1B). ASBTi treatment did not affect the absorp-
tion of the PUFA linoleic acid (C18:2𝜔6) (Figure 1B, 97.6 vs
97.5%, p = 0.9). In contrast, the absorption of SFAs was more
strongly reduced, by 6.5% for myristic acid (C14:0), by 14.8%
for palmitic acid (C16:0), and by 19.3% for stearic acid (C18:0)
(Figure 1C). In agreement with their higher BA-dependency for
absorption, the absorption of long chain SFAs was least efficient.
This is illustrated in Figure 1D where the absorption of the
major SFA species is plotted in relation to their reverse phase
high-performance liquid chromatography (HPLC) retention
time, a reflection of hydrophobicity.[23,24] Even at similar HPLC
retention times SFA absorption was more affected by ASBT in-
hibition than PUFA/MUFA absorption (Figure 1D–E). However,
the pattern for fatty acid absorption follows that for previously
published efficiency of micellar solubilization in the presence of
BAs and is aside from fatty acid hydrophobicity also dependent
on other factors such as the presence of phospholipids.[25]
2.2. ASBT Deficiency Reduces Diet-Induced Obesity and
Metabolic Disease Development
To assess the consequences of ASBT deficiency on diet-induced
obesity we fed mice with Asbt−/− mice a HFD enriched in sat-
urated fats (sHFD) and a matched low-fat control diet (sLFD).
Asbt−/− mice displayed less weight gain in response to sHFD as
compared to WT littermates, resulting in a significantly lower
body weight after 11 weeks of diet (Figure 2A,B, 36 vs 44 g,
p = 0.001). In contrast, no significant difference in weight gain
was observed for the sLFD between genotypes (Figure 2A).
Caloric intake and energy expenditure were not different be-
tween WT and Asbt−/− mice on either diet (Figure S1A,B, Sup-
porting Information). There was a trend toward a lower fat mass
(Figure 2C, 34 vs 41%, p = 0.07) and a higher lean mass (Fig-
ure 2C, 56 vs 51%, pP = 0.16) in Asbt−/− mice compared to WT
mice on a sHFD as determined by magnetic resonance imag-
ing (MRI). Omental, subcutaneous (inguinal) and brown, but not
visceral (epididymal) adipose tissue was significantly reduced in
Asbt−/− mice as compared to WT mice on a sHFD (Figure S1C,
Supporting Information). Histological examination of epididy-
mal adipose tissue of sHFD fedmice further revealed a reduction
in crown-like structures inAsbt−/− mice as compared toWTmice,
indicative of a reduction in adipocyte death and inflammation[26]
(Figure S2A–C, Supporting Information). Together these data
show that Asbt−/− mice are partially protected from diet-induced
on a sHFD.
To assess the effect of ASBT deficiency on glucose home-
ostasis, we performed an ITT, OGTT and measured fasting in-
sulin levels. sLFD feeding for 12 weeks did not induce differ-
ences in ITT, OGTT and plasma insulin between Asbt−/− andWT
mice (Figure S3A–E, Supporting Information). Asbt−/− mice, fed
a sHFD for 12 weeks, showed a pronounced improvement on
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Figure 1. The effect of ASBT inhibition on intestinal absorption of fatty acids. A) Total fat absorption, B) fat absorption of the main dietary MUFA and
PUFA species, and C) fat absorption of different SFA species in WT mice fed a tHFD with and without ASBT inhibitor (ASBTi); D) fat absorption of the
three major SFA and E) four major MUFA/PUFA plotted against their reverse phase HPLC retention time for WT mice fed a tHFD with and without an
ASBTi (n = 8). TFA, trans-fatty acid; *p < 0.05, **p < 0.01, ***p < 0.001.
insulin sensitivity (Figure 2D,E, AUC 1438 vs 898, p < 0.001).
This was accompanied by a lower plasma insulin levels after a 4
h fast in Asbt−/− compared to WT mice on the sHFD (Figure 2F,
0.7 vs 3.6 ng mL−1, p = 0.001). However, there was no difference
in glucose tolerance of Asbt−/− mice compared to WT controls
(Figure 2D,E, AUC 2324 vs 2155, p = 0.1).
2.3. ASBT Deficiency Prevents Development of High-Fat
Diet-Induced NAFLD
To determine whether previously observed effects on NAFLD
with an ASBTi are also present inAsbt−/- mice, wemeasured hep-
atic lipid content.[14] Both absolute liver weight and liver to body-
weight ratio were similar in Asbt−/− compared to WT mice fed
a sLFD, but significantly lower in Asbt−/− compared to WT mice
on a sHFD (Figure S4, Supporting Information, Figure 3A, 0.044
vs 0.032, p = 0.03). Hepatic TG levels after 16 weeks of sHFD
feeding were markedly higher in WT compared to Asbt−/− mice
(Figure 3B, 221 vs 46 𝜇mol g−1, p< 0.001) and not different when
fed a sLFD (Figure 3B).Asbt knockout was effective in preventing
hepatic cholesterol accumulation, both in sLFD and sHFD fed
mice (Figure 3C, 4.1 vs 6.1 𝜇mol g−1, p = 0.05; 4.2 vs 9.5 𝜇mol
g−1, p< 0.001; inAsbt−/− andWTmice, respectively). Liver histol-
ogy showed a significantly lower NAS in Asbt−/− mice compared
to WT mice fed a sHFD (Figure 3D–F).
2.4. Fecal Fatty Acid Excretion is Increased and Biliary
Bile Acid Secretion Decreased in Asbt−/− Mice Fed an
SFA-Rich HFD
We hypothesized that the reduced fat absorption observed upon
ASBT inhibition is the result of less efficient micellar solubiliza-
tion due to lower intestinal BA concentrations. Indeed, biliary BA
secretion in Asbt−/− mice was 47% lower compared to WT mice
fed a sHFD (Figure 4A, 70 vs 132 𝜇mol per 24 h per 100 g BW,
p = 0.03). The bile of Asbt−/− mice contained relatively more
tauro-deoxycholic acid (T-DCA) and less tauro-beta-muricholic
acid (T-𝛽MCA) as compared to WT mice, which resulted in a
more hydrophobic BA composition[27] (Figure S5A,B, Supporting
Information). Fecal excretion of BAs was significantly increased
in Asbt−/− mice on the sLFD and further increased on the sHFD
(Figure S5C, Supporting Information). Total fecal fat excretion
was significantly higher in Asbt−/− mice compared to WT mice
fed a sHFD (Figure 4B, 79 vs 24 𝜇mol per 24 h, p < 0.001). Fe-
cal excretion of SFAs was significantly increased by 2.2-fold for
myristic acid (C14:0), 3.3-fold for palmitic acid (C16:0), and 3.4-
fold for stearic acid (C18:0) (Figure 4C) in Asbt−/− compared to
WT mice on a sHFD). Absolute fatty acid excretion was higher
for theMUFAs, vaccenic (C18:1𝜔7), and oleic acid (C18:1𝜔9) and
lower for the PUFAs, linoleic (C18:2𝜔6), and alpha linoleic acid
(C18:3𝜔3) (Figure 4D). Fecal excretion of all unsaturated fatty
acids was increased by ≈threefold in Asbt−/− compared to WT
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Figure 2. The effect of ASBT deficiency on diet-induced obesity and related glucose homeostasis. A) Time course of bodyweight gain expressed as
percentage of starting bodyweight, B) bodyweight at week 11 of WT and Asbt−/− mice on sLFD and sHFD, C) body composition after 12 weeks of sLFD
and sHFD diet, D) intraperitoneal ITT and E) area under the curve (AUC), F) plasma insulin levels in WT and Asbt−/- mice fed a sHFD G) OGTT and H)
AUC; n = 9 to 10. Different lowercase letters indicate statistically significant differences (p < 0.05) between four groups. Between two groups statistical
difference is indicated as *p < 0.05, **p < 0.01, ***p < 0.001.
mice. However, the absorption of SFAs was more affected than
that of the PUFAs, as indicated by an increased fecal SFA:PUFA
ratio of Asbt−/− mice (Figure 4E). Fecal neutral sterol excretion
was also increased in Asbt−/− mice on the sHFD (Figure S5D,
Supporting Information). On the sLFD diet, biliary BA secretion
was also lower and total fecal fatty acid excretion higher inAsbt−/−
mice compared to WTmice (Figure S6A,B, Supporting Informa-
tion). The increase in fecal fatty acid excretion could bemainly at-
tributed to higher SFA excretion, especially C18:0 (Figure S6C–E,
Supporting Information).
Altogether these data indicate a reduced intestinal lipid absorp-
tion, particularly of SFAs in Asbt−/− mice.
2.5. Dietary Fat Composition Modulates Some of the Effects of
Diet-Induced Obesity in Asbt−/− Mice
We next determined whether the effects on specific fatty acid ab-
sorption had an impact on diet-induced obesity by modulating
dietary fatty acid composition. To this end we compared the lard
based sHFD with a diet with similar fat content but based on
soybean and canola oil (pHFD) (Table S1, Supporting Informa-
tion). The caloric intake on the pHFD was lower, but this did
not reach statistical significance (Figure S7, Supporting Informa-
tion). After 11 weeks on diet, Asbt−/− mice had a significantly
lower body weight than WT mice on a sHFD (Figure 5A,B, 40
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Figure 3. Non-alcoholic fatty liver disease (NAFLD) in Asbt−/− and WT mice fed a sHFD. A) Liver weight to body weight ratio; B) hepatic TG and C)
hepatic total cholesterol in mice fed the sLFD and sHFD, n = 8 to 10; D) H&E staining of WT mouse liver after sHFD feeding, E) H&E staining of
Asbt−/− mouse liver after sHFD feeding, representative samples; F) NAFLD activity score (NAS) based on histology, n = 4 to 5. Different lowercase
letters indicate statistically significant differences (p < 0.05) between four groups. Between two groups statistical difference is indicated as *p < 0.05,
**p < 0.01, ***p < 0.001.
vs 45 g, p = 0.04) but not on the pHFD. Both WT and Asbt−/−
mice on the pHFD had less fat mass and more lean mass com-
pared to their respective sHFD controls (Figure 5C). ASBT in-
activation had no additional effect on body composition on ei-
ther diet. Insulin tolerance was significantly improved in Asbt−/-
mice on a sHFD after 12 weeks (AUC 1123 vs 1543, p = 0.004,
Figure 5D,E). Plasma insulin levels were impacted by both mod-
ulating diet (p = 0.02) and genotype (p = 0.002) without inter-
action (Figure 5F). Post-hoc analysis showed no significant dif-
ferences between groups. However, there was a trend of lower
insulin levels in Asbt−/− compared to WT mice on the sHFD
(3.7 vs 5.1 ng mL−1, p = 0.05) which was less pronounced on
the pHFD (3.0 vs 4.0, p = 0.2). Neither modulating the dietary
fat composition nor ASBT inactivation affected glucose tolerance
(Figure 5G,H).
Altogether, compared to WT mice on the same diet, Asbt−/−
mice only displayed a significant reduction in bodyweight gain
on the sHFD and not the pHFD.
2.6. Intestinal Fat Absorption is Higher on a Diet Rich in
Polyunsaturated Fatty Acids Compared to Saturated Fatty Acids
in both WT and Asbt−/− Mice
We next examined whether modulating dietary fat composition
affected BA homeostasis and lipid absorption. In WT mice
fecal BA and neutral sterol excretion were unaffected by dietary
fatty acid composition (Figure S8A,B, Supporting Information).
Asbt−/− mice had strongly increased fecal BA and neutral sterol
excretion compared to their respective controls. Interestingly,
Asbt−/− mice on the pHFD had slightly lower fecal BA excretion
compared to the sHFD (Figure S8A, Supporting Information).
Biliary BA excretion was about 45% lower for bothAsbt−/− groups
compared to WT, and was unaffected by dietary composition
(Figure 6A). Both Asbt−/− groups had higher concentrations of
T-DCA compared to WT, resulting in a higher hydrophobicity
index (Figure S8C, Supporting Information).
Total fecal fat excretion was ≈60% lower in WT mice on a
pHFD compared to the sHFD (p < 0.001, Figure 6B). Total fat
excretion in Asbt−/−mice was also lower on the pHFD compared
to the sHFD (p < 0.001, Figure 6B). This observation was re-
flected in total fatty acid absorption, which was higher in both
pHFD groups compared to the sHFD groups (Figure 6C). The
decrease in total fatty acid absorption was ≈10% for Asbt−/− mice
compared to WT mice on the sHFD (p < 0.001, Figure 6C) and
was ≈5% on the pHFD (p < 0.001, Figure 6C). SFA absorption
was overall decreased on the sHFD but most pronounced for
C16:0 and C18:0 with absorption for C18:0 being as low as 0%
for Asbt−/− mice on the sHFD (Figure 6D). The absorption of
MUFAs was higher on the pHFD than on the sHFD (Figure 6E).
For the main dietary PUFA, linoleic acid (C18:2𝜔6), Asbt−/− mice
showed a similar reduction on either diet compared to their
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Figure 4. Biliary bile acid secretion and fecal fatty acid excretion in Asbt−/- mice fed a sHFD. Biliary BA secretion of WT and Asbt−/− mice A) after 16
weeks of sHFD; B) total fecal fat excretion, C) fecal excretion of the main SFAs, and D) of the main MUFAs/PUFAs; E) the ratio of fecal excretion of SFAs
to PUFAs in WT and Asbt−/− mice on the sHFD, n = 9 to 10. Statistical differences are indicated as *p < 0.05, **p < 0.01, ***p < 0.001.
respective controls (98.3% vs 99.1% for sHFD, p < 0.001, 98.3%
vs 99.5% for pHFD, p < 0.001, Figure 6E).
These data show that absorption of fatty acids was generally
more efficient on the pHFD compared to the sHFD. In line with
greater BA dependency, SFA absorption was most profoundly af-
fected in Asbt−/− mice, especially on the sHFD.
2.7. Asbt−/− Mice Are Protected against Diet-Induced NAFLD on
a Diet Rich in Saturated Compared to Polyunsaturated Fatty Acids
Previously, it has been shown that ASBT inhibition robustly
prevents hepatic lipid accumulation in mice.[14,18] In our current
experiment, liver-to-bodyweight ratio was not different in WT
mice fed a sHFD or pHFD (Figure 7A). Asbt−/− mice on either
diet had a decreased liver-to-bodyweight ratio compared to their
respective controls but this difference was more pronounced
on the sHFD. Hepatic TG content (Figure 7B) was 55% lower
in Asbt−/− compared to WT mice on the sHFD (75 vs 168 𝜇mol
g−1 liver, p = 0.004) and 40% lower on the pHFD (124 vs 205
𝜇mol g−1, p = 0.01). In Asbt−/- mice, both total fat absorption and
the absorption of C16:0 were positively correlated to hepatic TG
level (Spearman r = 0.55, p = 0.01, Figure S9A,B, Supporting
Information). Hepatic total cholesterol levels were similarly
lower by ≈30% in Asbt−/− mice on either diet compared with
WT (Figure 7C). Histological analysis showed a significantly
lower NAS in Asbt−/− compared to WT mice fed a sHFD (1.6 vs
4.3, p = 0.02, Figure 7D,E,H). NAS was not significantly lower
in Asbt−/− compared to WT mice on the pHFD (2.3 vs 3.3, p
= 0.65, Figure 7F–H). The higher absolute uptake of PUFAs
on the pHFD was associated with elevated concentrations of
both linoleic (C18:2𝜔6) and alpha-linoleic acid (C18:3𝜔3) in the
hepatic fatty acid profile (Figure 8).
These data demonstrate that modulating dietary fatty acid
composition did not significantly affect NAFLD outcomes in WT
mice. While Asbt−/− mice displayed reduced hepatic lipid accu-
mulation on either diet, the NAS was only lower in Asbt−/− mice
on the sHFD and not on the pHFD, indicating thatAsbt knockout
was more effective in the prevention of NAFLD on the sHFD.
3. Discussion
We determined the effects of inhibiting ASBT-mediated intesti-
nal BA absorption on the intestinal absorption of fatty acids, and
on diet-induced metabolic dysfunction. Cholesterol and long-
chain SFAs are more dependent on micellar solubilization by
BAs for their absorption from the intestinal lumen than PUFAs
or short-chain fatty acids.[7,28,29] Here, we show that inhibition of
ASBT in mice decreased total intestinal absorption of fatty acids
and the effect was most prominent for SFA species. While the
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Figure 5. Bodyweight gain and glucose homeostasis in Asbt−/− and WT mice fed a sHFD and pHFD. A) Time course of bodyweight gain expressed as
percentage of starting bodyweight, B) bodyweight at week 11 of WT and Asbt−/− mice on sHFD and pHFD, C) body composition after 12 weeks of sLFD
and sHFD diet, D) intraperitoneal ITT and E) AUC, F) OGTT, and G) area under the curve (AUC), H) plasma insulin levels in WT and Asbt−/- mice fed a
sHFD and pHFD; n = 10. Different lowercase letters indicate statistically significant differences (p < 0.05) between groups.
reduction in specific fatty acid absorption was correlated to liter-
ature values of their HPLC retention time, a surrogate measure
for hydrophobicity, and in turn BA-dependency, other factors af-
fecting solubilization are likely to be involved as well. The phys-
iological solubilization in the intestinal lumen varies greatly for
different fatty acid species and is influenced by the CMC of in-
testinal BAs, the other components of mixed micelles (such as
phospholipids and cholesterol), and the pH level.[24,25,30] Inter-
estingly, significant beneficial effects on obesity and insulin re-
sistance were only observed in a SFA-rich HFD, indicating that
dietary fat composition and specific reduction of SFA absorption
modulated these effects. While Asbt−/− mice were (partially) pro-
tected from hepatic TG accumulation irrespective of dietary fatty
acid composition, the NAS was only lower in Asbt−/− mice on a
SFA-rich HFD. Together these results demonstrate that several
of the beneficial metabolic effects of ASBT inhibition correspond
with its differential inhibitory effect on dietary fatty acid absorp-
tion.
Total fat absorption inAsbt−/− mice was reduced to a greater ex-
tent on the sHFD (−10%) than on the soybean and pHFD (−5%),
when compared to WT controls. This is in line with the sHFD
higher content of SFAs, which are more dependent on BAs for
absorption. Asbt−/− mice fed a sHFD but not a pHFD gained less
weight and had reduced insulin resistance compared to WT lit-
termates fed the same diet. This could be explained either by a
direct effect of absorbing fewer calories from fat or by an indi-
rect effect (e.g., hormonal or microbial). An indirect effect is in
line with a previous suggestion that when more fatty acids reach
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Figure 6. Biliary bile acid secretion and fecal fatty acid excretion in Asbt−/- mice fed a sHFD and pHFD. A) biliary BA secretion, B) total fecal fatty
acid excretion, and C) total intestinal fatty acid absorption on the sHFD and pHFD, n = 8 to 10. Intestinal absorption of D) the main SFA and E) the
PUFAs/MUFAs of WT and Asbt−/− mice on the sHFD and pHFD, n = 10. Different lowercase letters indicate statistically significant differences (p <
0.05) between groups.
the distal intestine, they increase glucagon-like peptide-1 (GLP-1)
release, resulting in improved glucose homeostasis.[31] Unfortu-
nately, we were unable to assess GLP-1 secretion in our current
study.
Dietary fat composition also impacted fatty acid absorption in
WT mice. Total fat absorption in WT mice was lower on a sHFD
(88%) than on a pHFD (98%). Generally, SFA absorption was
less efficient than MUFA or PUFA absorption (Figure 1). In-
creasing dietary SFA content lowered total intestinal fat absorp-
tion, even inWTmice. However, not only total but also fractional
SFA absorption in mice fed the sHFD was lower than on the
pHFD (Figure 6). Under physiological conditions, intestinal fatty
acid absorption is highly efficient (>95%) and adapts to dietary
concentrations.[32] However, chronic HFD feeding by itself has
been shown to decrease intestinal fat absorption in mice, which
could be differentially affected depending on the dietary fatty acid
profile.[33]
Previous studies have reported a robust prevention of hepatic
TG accumulation upon ASBT inhibition or genetic inactivation
in mice.[14,18] We also found strongly decreased hepatic lipid
accumulation in Asbt−/− mice irrespective of dietary fatty acid
composition. However, the preventative effect of ASBT inacti-
vation on hepatic TG accumulation was more pronounced on
the sHFD compared to the pHFD. Additionally, the NAS was
only reduced in Asbt−/− mice fed the sHFD and not the pHFD.
The reduction in fat absorption correlated to the lowering of
hepatic TG accumulation suggesting a relationship between the
two. This is in line with a previous study where the beneficial
effects of ASBT inhibition on NAFLD development were lost
on a CDAA diet that also normalized the inhibitory effects on
fat absorption.[10] Although the reduction in fat absorption can
partially explain the effects on NAFLD, other changes such as
reduced activation of FXR, increased activation of TGR5, or shifts
in microbiota composition likely contribute. The shift towards
more DCA in the BA pool of Asbt−/− mice could have an effect
independent of fat absorption, for example via TGR5 or hepatic
FXR activation.[14] A recent study demonstrated that intraduode-
nal injections of TCA and especially DCA, lowered postprandial
plasma lipids, suggesting an additional (receptor-mediated)
effect of these BAs on intestinal lipid handling.[34]
We noted that there were differences in metabolic improve-
ments between the different experiments using the same sHFD.
A potential explanation for this difference is that the age and the
bodyweight of mice used in the second experiment were higher
compared to the first experiment (10.9 vs 8.5 weeks; and, 26.8
vs 24.2 g, respectively). Furthermore, both the sHFD and pHFD
were administrated as paste instead of pellets during the second
experiment. Dietary form has been shown to alter food intake
and bodyweight gain in mice and could have affected the differ-
ent outcomes.[35]
Together, our data show that ASBT deficiency impairs intesti-
nal fatty acid absorption, particularly of SFAs, which is largely re-
sponsible for the beneficial effects observed on diet-induced obe-
sity and NAFLD in Asbt−/− mice. Changing the dietary composi-
tion to amore PUFA based diet increased total fat absorption and
decreased the beneficial effects on diet-induced obesity observed
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Figure 7. Non-alcoholic fatty liver disease (NAFLD) development in WT and Asbt−/− mice fed different HFDs. A) Liver weight to body weight ratio; B)
liver TGs and C) hepatic total cholesterol in mice fed a sHFD and pHFD, n = 10; H&E staining of D) WT mouse liver and E) Asbt−/− mouse liver after
sHFD feeding, and F) WT mouse liver and G) Asbt−/− mouse liver after pHFD feeding, representative samples; H) NAS, n = 10. Different lowercase
letters indicate statistically significant differences (p < 0.05) between groups.
Figure 8. Liver fatty acid profile in WT and Asbt−/− mice fed the sHFD or pHFD, n = 10. Different lowercase letters indicate statistically significant
differences (p < 0.05) between groups.
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inAsbt−/− mice compared toWTmice on the same diet. Addition-
ally, a higher intestinal (saturated) fatty acid absorption inAsbt−/−
mice correlated to a higher hepatic triglyceride content. The dif-
ferences in metabolic outcomes using distinct HFDs highlight
the importance of dietary fat composition in metabolic research
interpretation and design in mice, and perhaps also in humans.
The implications of this study for human physiology and therapy
require further investigation as human BA profiles are different
(i.e., the absence of hydrophilic MCAs) and fat absorption might
be affected differently by ASBT inhibition. Nevertheless, based
on these preclinical findings, the effectiveness of ASBT inhibi-
tion on metabolic outcomes is likely dependent on dietary fatty
acid content and profile. Therefore, diet composition should be
taken into consideration when designing new experiments and
assessing the therapeutic efficacy of ASBT inhibition and other
therapies related to the manipulation of the enterohepatic circu-
lation of BAs.
4. Experimental Section
Animals: For the experiment with the ASBT inhibitor (ASBTi), male
C57Bl/6J mice aged 8 weeks were obtained from Jackson Laboratories. An-
imals were initially group-housed and then individually housed for 1 week
during the fat absorption measurements at 23 °C and a 12-h light/dark cy-
cle. Mice received a 45% trans-fat HFD (tHFD, Harlan Teklad TD130885,
ALIOS custom diet with 0.2% added cholesterol) plus 0.006% w/w of an
ASBT inhibitor (ASBTi, SC-435, Lumena Pharmaceuticals/Shire,MA, USA)
ad libitum for 2 weeks. The Emory University Institutional Animal Care and
Use Committee approved these experiments (protocol #4000003).
Asbt−/− mice and wild type littermates on a>99%C57BL/6 background
were generated by P.A. Dawson and bred at the animal facility of the Uni-
versity Medical Center Groningen. Males aged 8–15 weeks were conven-
tionally housed in a temperature- and light-controlled facility with a 12-
h light/dark cycle. Mice had ad libitum access to water and a 60% SFA
rich high-fat diet (sHFD, Research Diets Inc., NJ, USA, #D12492) or PUFA
rich high-fat diet (pHFD, Research Diets Inc., NJ, USA, #D17122702Mi)
or matched SFA based low fat control diet (sLFD, Research Diets Inc., NJ,
USA, #D12450J). Table S1, Supporting Information shows the fatty acid
compositions of the different diets used. Mice were individually housed
and received the experimental diet for a total of 16 weeks. These animal
experiments were approved by the Ethics Committee for Animal Experi-
ments of the University of Groningen (protocol #15245-03-05/020/036).
All experiments were performed in accordance with relevant guidelines
and regulations (including laboratory and biosafety regulations).
Dosage Information: Mice received the ASBTi (SC-435) uniformly
mixed in the diet at 0.006% w/w. This equates to 6.7 mg kg−1 bodyweight
per day, calculated using average bodyweight and food intake data (Table
S2, Supporting Information). This dosage in mice translates to a human
equivalent dose (HED) of 0.5 mg kg−1 bodyweight.[36]
Animal Experiments: Bodyweight was determined biweekly. Body com-
position was determined by magnetic resonance imaging using a MiniS-
pec LF90 Body Composition Analysis (Bruker Biospin, Germany). After 16
weeksmice were anesthetized using amixture of intraperitoneal Hypnorm
(fentanyl/fluanisone; 1 mL kg−1) and diazepam (10 mg kg−1). The com-
mon bile duct was cannulated as described before.[37] Bile collected in the
first 5 min was discarded and collected for the subsequent 20 min Blood
was obtained via cardiac puncture. Livers were excised, weighed and snap
frozen in liquid nitrogen.
Fatty Acid Absorption: Mice were individually housed during the sec-
ond week of the experiment and received powdered tHFD or sHFD/pHFD
in paste containing 0.7% sucrose polybehenate w/w (SEFOSE 2275; Proc-
tor and Gamble, Cincinnati, OH) as a nonabsorbable marker.[38] Chemical
hydrolysis of dietary or fecal samples liberates the behenic acid permitting
determination of the fatty acid to behenic acid ratios. Feces were collected
for the final 3 days of the experiment.
Diet and feces were saponified with methanolic NaOH, extracted with
hexane, converted to methyl esters, and analyzed by gas chromatography
to quantitate behenic acid (C22:0) and other fatty acids.[39] The coeffi-
cient of absorption for each FA was calculated as {1 − (FA/C22:0)feces /
(FA/C22:0)diet} × 100.
Glucose Homeostasis: Oral glucose tolerance tests (OGTT) were per-
formed following oral administration of D-glucose at 2 g kg−1 body weight
after an overnight fast. Insulin tolerance tests (ITT) were performed follow-
ing intraperitoneal administration of insulin (Novorapid, Novo Nordisk,
Denmark) at 0.5 U kg−1 bodyweight for sLFD mice, and 1 U kg−1 body
weight for sHFD and pHFD mice after a 6 h fast. Blood glucose was
measured using a OneTouch Ultra glucometer (Lifescan Inc, USA) for
the sHFD/sLFD experiment and using an Accu-Chek Performa glucome-
ter (Roche, Switzerland) for the sHFD/pHFD experiment. Plasma insulin
concentrations were determined using the ultra-sensitive rat insulin ELISA
kit, withmouse insulin standard fromCrystal Chem (Cat. 90010 and 90020,
Zaandam, The Netherlands).
Histology: Formalin-fixed and paraffin-embedded hematoxylin and
eosin (H&E) stained slides of liver and epididymal adipose tissue were
used for histopathologic examination. Slides were examined and scored
blindly, and findings were reviewed by veterinary pathologists (authors LB,
RT, and AdB). H&E liver specimens were evaluated using the modified
version of NAFLD activity score (NAS) scoring for as detailed by Kleiner
et al.[40] which combines each component of the NAS; steatosis (0=<5%;
1 = 5 to 33%; 2 = 33 to 66%; 3 = >66%), lobular inflammation (0–3), bal-
looning (0–2). Ballooned hepatocytes are recognized as being markedly
enlarged with pale vacuolated cytoplasm and a centrally located and com-
pressed nucleus. Lobular inflammation was recognized as small clusters
(>5 cells) of mixed inflammatory cells scattered throughout the hepatic
parenchyma; in many cases these were characterized by groups of mixed
inflammatory cells, mainly lymphocytes and neutrophils (counts were per-
formed over 5 × 200 fields), occasionally associated with single-cell necro-
sis. Paraffin-embedded H&E stained slides of adipose tissue were ana-
lyzed using digital image analysis software.[41] Crown-like structures, in-
dicative of adipocyte death and macrophage infiltration,[26] were counted
over 5 × 200 fields.
Bile Acid and Neutral Sterol Measurements: Neutral sterols (choles-
terol and its bacterial metabolites) were extracted from 50 mg of air-dried,
ground fecal samples as described by Ronda et al.[42] BAs were extracted
from feces with Sep-Pak C-18 columns, methylated with methanol/acetyl
chloride (20:1) and derivatized with BSTFA-pyridine-TMCS (5:5:0.1). Both
neutral sterols and BAs were measured by gas chromatography (GC) as
previously described.[43] The total amount of BAs or neutral sterols was
calculated as the sum of the individual species.
Biliary BA concentrationsweremeasured usingUltraHigh Performance
Liquid Chromatography coupled to a triple quadrupolemass spectrometer
(UPLC-MS/MS) as previously described.[11]
Hepatic Lipids: Hepatic lipids for the experiment with the ASBTi were
extracted according to the Folch method.[44] Briefly, lipids were extracted
from ≈60 mg liver tissue using 3 mL of chloroform: methanol (2:1) and
incubated at 55 °C for at least 2 h. Phases were separated by adding 0.05%
v/v sulfuric acid in water and centrifugation at 1500 rpm for 15 min. Part
of the bottom layer was transferred, dried down under nitrogen and dis-
solved in 2% v/v TritonX-100 in water. Hepatic concentrations of total
cholesterol (Pointe Scientific, C7510-01-906), free cholesterol (Wako Di-
agnostics, Cat# 993-02501), and TG (Wako Diagnostics, Cat#994-02891
and 990-02991) were subsequently measured by enzymatic assays.
Livers from the experiments with Asbt−/− mice were mechanically ho-
mogenized in liquid nitrogen. Lipids were extracted from 10% to 15% ho-
mogenates in PBS according to Bligh and Dyer.[45] Subsequently, total and
free cholesterol and TG levels were determined using commercially avail-
able reagents (DiaSysDiagnostic Systems,Holzheim,Germany and Roche
Diagnostics, Mannheim, Germany).
Statistical Analyses: Statistical analyses were performed and graphs
were created using GraphPad Prism 6 (GraphPad Software, La Jolla, CA,
USA). Data are presented as mean ± standard deviation (SD), unless
stated otherwise. Differences between 4 groups were assessed by 2-way
ANOVA using Tukey’s post-hoc test. Differences between two groups were
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determined with aMann–Whitney U test. Significant differences (p< 0.05)
between groups when assessing four groups is indicated by different low-
ercase letters. Statistical difference between two groups is indicated as *p
< 0.05, **p < 0.01, ***p < 0.001.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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